Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Analysts
Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat reports. Three...